Ionis Pharmaceuticals Inc. Common Stock vs Wendys Co — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $43.32 (market cap $7.10B), while Wendys Co trades at $6.46 (market cap $1.23B). The key difference: Ionis Pharmaceuticals Inc. Common Stock is far larger — about 5.8× Wendys Co's market cap, and Wendys Co pays a 4.35% dividend while Ionis Pharmaceuticals Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and Wendys Co for 78 Days on average.
| IONS | WEN | |
|---|---|---|
Market Cap | $7.10B | $1.23B |
Volume | 2,027,457 | 6,130,931 |
Sector | Health | Consumer Cyclical |
52-Week High | $86.50 | $9.33 |
52-Week Low | $42.38 | $6.10 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $6.66B | $4.96B |
Dividend Yield | — | 4.35% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wendy's (WEN) trades at $6.35, up 0.63% with a bearish technical outlook. The stock shows attractive valuation metrics with a P/E of 9.62 and P/S of 0.55, but faces fundamental challenges including declining net income margins (5.72% in 2026) and high debt levels. Recent news highlights franchisee bankruptcies and competitive pressures, though the company has beaten earnings expectations for three consecutive quarters. Analyst consensus remains cautious with a $7.58 price target and 64.71% hold rating.
The investment case balances deep value against operational headwinds. While valuation appears compelling, declining profitability, franchisee instability, and intense competition create significant risks. The stock offers a dividend yield but requires successful execution under new leadership to reverse negative trends. Near-term catalysts include Q3 2026 earnings and management's turnaround strategy implementation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →